vs
Side-by-side financial comparison of Massimo Group (MAMO) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
Massimo Group is the larger business by last-quarter revenue ($21.0M vs $19.1M, roughly 1.1× NewAmsterdam Pharma Co N.V.). Massimo Group runs the higher net margin — 9.5% vs -90.7%, a 100.2% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs 15.7%).
Massimo Dutti, S.A. is a Spanish premium clothing retailer specializing in cashmere and wool products, established in 1985 and owned by Spanish multinational company Inditex, the parent company of Zara, Pull&Bear, and other brands.
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
MAMO vs NAMS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.0M | $19.1M |
| Net Profit | $2.0M | $-17.4M |
| Gross Margin | 41.5% | — |
| Operating Margin | 13.1% | -186.1% |
| Net Margin | 9.5% | -90.7% |
| Revenue YoY | 15.7% | 740.1% |
| Net Profit YoY | 215.0% | 55.5% |
| EPS (diluted) | $0.05 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.0M | — | ||
| Q3 25 | $17.0M | — | ||
| Q2 25 | $18.9M | $19.1M | ||
| Q1 25 | $14.9M | — | ||
| Q4 24 | $18.2M | $12.8M | ||
| Q3 24 | $25.6M | $29.1M | ||
| Q2 24 | $35.4M | — | ||
| Q1 24 | $30.2M | — |
| Q4 25 | $2.0M | — | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $77.7K | $-17.4M | ||
| Q1 25 | $-2.1M | — | ||
| Q4 24 | $-1.7M | $-92.2M | ||
| Q3 24 | $-2.5M | $-16.6M | ||
| Q2 24 | $2.8M | — | ||
| Q1 24 | $3.2M | — |
| Q4 25 | 41.5% | — | ||
| Q3 25 | 42.0% | — | ||
| Q2 25 | 36.3% | — | ||
| Q1 25 | 28.4% | — | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 27.2% | — | ||
| Q2 24 | 32.5% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 13.1% | — | ||
| Q3 25 | 10.5% | — | ||
| Q2 25 | 0.8% | -186.1% | ||
| Q1 25 | -18.2% | — | ||
| Q4 24 | -15.4% | -338.5% | ||
| Q3 24 | 1.2% | -85.9% | ||
| Q2 24 | 10.1% | — | ||
| Q1 24 | 13.2% | — |
| Q4 25 | 9.5% | — | ||
| Q3 25 | 9.0% | — | ||
| Q2 25 | 0.4% | -90.7% | ||
| Q1 25 | -14.0% | — | ||
| Q4 24 | -9.5% | -721.7% | ||
| Q3 24 | -9.8% | -57.2% | ||
| Q2 24 | 8.0% | — | ||
| Q1 24 | 10.6% | — |
| Q4 25 | $0.05 | — | ||
| Q3 25 | $0.04 | — | ||
| Q2 25 | $0.00 | $-0.15 | ||
| Q1 25 | $-0.05 | — | ||
| Q4 24 | $-0.05 | $-0.91 | ||
| Q3 24 | $-0.06 | $-0.18 | ||
| Q2 24 | $0.07 | — | ||
| Q1 24 | $0.08 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.8M | $739.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $23.7M | $778.5M |
| Total Assets | $51.4M | $815.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.8M | — | ||
| Q3 25 | $2.6M | — | ||
| Q2 25 | — | $739.2M | ||
| Q1 25 | $3.0M | — | ||
| Q4 24 | $10.2M | $834.2M | ||
| Q3 24 | — | $422.7M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $23.7M | — | ||
| Q3 25 | $21.7M | — | ||
| Q2 25 | $20.2M | $778.5M | ||
| Q1 25 | $19.9M | — | ||
| Q4 24 | $21.7M | $757.5M | ||
| Q3 24 | $22.5M | $378.9M | ||
| Q2 24 | $24.7M | — | ||
| Q1 24 | $18.1M | — |
| Q4 25 | $51.4M | — | ||
| Q3 25 | $44.4M | — | ||
| Q2 25 | $45.9M | $815.1M | ||
| Q1 25 | $46.4M | — | ||
| Q4 24 | $54.9M | $864.6M | ||
| Q3 24 | $57.1M | $439.2M | ||
| Q2 24 | $49.9M | — | ||
| Q1 24 | $47.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.0M | $-37.7M |
| Free Cash FlowOCF − Capex | — | $-37.8M |
| FCF MarginFCF / Revenue | — | -197.2% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | 2.01× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.0M | — | ||
| Q3 25 | $633.2K | — | ||
| Q2 25 | $-1.4M | $-37.7M | ||
| Q1 25 | $-3.3M | — | ||
| Q4 24 | $9.1M | $-37.5M | ||
| Q3 24 | $4.7M | $-12.5M | ||
| Q2 24 | $-6.5M | — | ||
| Q1 24 | $-637.0K | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-37.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | $9.0M | $-37.5M | ||
| Q3 24 | $4.6M | $-12.6M | ||
| Q2 24 | $-6.7M | — | ||
| Q1 24 | $-741.4K | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -197.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | 49.7% | -293.5% | ||
| Q3 24 | 18.1% | -43.2% | ||
| Q2 24 | -19.0% | — | ||
| Q1 24 | -2.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.2% | 0.0% | ||
| Q3 24 | 0.3% | 0.3% | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 2.01× | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | -17.92× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.30× | — | ||
| Q1 24 | -0.20× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
